on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma.
The versatile Prezia Sustained Drug Delivery Technology platform is based on extensive scientific research that has resulted in the creation of a unique method for precise and controlled drug delivery.
PolyActiva and RareSight Inc. have announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments.
The research collaboration agreement, leveraging PolyActiva’s proprietary PREZIA™ platform, will offer first-of-its-kind, new chemical entity (NCE)-eligible pro-drug candidates to people affected by blinding eye conditions.
PolyActiva’s Chief Scientific Officer, Michael Brubaker, Ph.D., will present a corporate overview of the company’s proprietary PREZIA™ drug delivery platform at Eyecelerator @ the American Academy of Ophthalmology (AAO) 2025 Annual Meeting on Thursday, October 16, 2025, in Orlando, Florida.